Tirosint Cost in Montana 2026: Cash Price, Insurance, Medicaid, and Cheaper Alternatives

What Is Tirosint and Why Do Some Patients Need It Specifically?

Tirosint is a brand-name levothyroxine product manufactured by IBSA Institut Biochimique SA. It comes in two forms: a soft gel capsule (Tirosint) and a liquid solution in unit-dose ampules (Tirosint-SOL). Both contain only levothyroxine sodium dissolved in gelatin, glycerin, and water, with no dyes, no acacia, and no additional fillers that are present in conventional levothyroxine tablets.

That matters clinically. Standard levothyroxine tablets rely on consistent gastrointestinal absorption, and several common factors disrupt that process. Vita et al. (2014) demonstrated in a prospective crossover study that patients with autoimmune gastritis, Helicobacter pylori infection, or lactose intolerance achieved significantly better TSH normalization on liquid levothyroxine than on tablet formulations, with TSH falling from a mean of 3.85 mIU/L on tablets to 1.77 mIU/L on liquid levothyroxine (P<0.001) [1]. A follow-up analysis published via PubMed confirmed that the liquid and gel-cap forms bypass the dissolution step that causes erratic absorption in patients with gastric acid disorders [2].

The FDA-approved prescribing label for Tirosint specifies that the gel capsule should be taken on an empty stomach, 30 to 60 minutes before food, and that bioavailability may still be affected by calcium carbonate, iron sulfate, and proton pump inhibitors [3]. Patients on any of those agents who still show persistently elevated TSH despite adequate tablet doses are the primary candidates a clinician might consider for Tirosint.

The Endocrine Society clinical practice guidelines on hypothyroidism management recommend treating to a TSH goal of 0.5 to 2.5 mIU/L for most adults, with individualized targets for patients over 70 or those with cardiac disease [4]. When a tablet-formulated levothyroxine cannot reliably achieve that target, a specialty formulation becomes a medically defensible option rather than a preference.

What Does Tirosint Actually Cost in Montana in 2026?

The cash-pay price for a 30-day supply of Tirosint in Montana runs approximately $230 per month at most retail pharmacies in 2026. That figure represents the manufacturer's list price and does not change substantially between Billings, Missoula, Great Falls, or rural independent pharmacies because Tirosint has no generic equivalent, so there is no competitive pressure on retail price.

For context, generic levothyroxine tablets (25 mcg through 200 mcg) are available at most Montana pharmacies for $4 to $15 per month under GoodRx or similar discount programs [5]. The price gap between generic levothyroxine and Tirosint is therefore roughly $215 to $225 per month. That gap is why payers, including Montana Medicaid, typically require documented evidence of medical necessity before approving the brand product, and why they often still deny it.

GoodRx coupons for Tirosint bring the price down modestly at some Montana pharmacies, but savings are inconsistent. GoodRx's own database shows Tirosint prices ranging from approximately $175 to $230 across Montana zip codes depending on pharmacy contract, and those prices remain well above what most uninsured patients can sustain long-term [6].

The HealthRX clinical team uses the following decision framework when a Montana patient asks about Tirosint affordability:

1. Confirm the clinical indication: persistent TSH elevation despite adequate tablet dose, documented absorption barrier, or genuine excipient intolerance.
2. Check commercial insurance formulary status before writing the prescription.
3. Apply the IBSA savings card at the point of dispensing for commercially insured patients who meet eligibility criteria.
4. If uninsured or Medicaid-covered, assess whether a compounded levothyroxine gel capsule through a licensed Montana 503A pharmacy is clinically equivalent and cost-effective.
5. Reserve Tirosint-SOL (liquid ampules) for patients who cannot swallow capsules or who have demonstrated superior TSH control on the liquid form specifically.

Does Montana Medicaid Cover Tirosint?

Montana Medicaid does not cover Tirosint as of 2026. The Montana Medicaid preferred drug list does not include Tirosint or Tirosint-SOL among its covered levothyroxine products. Covered options under Montana Medicaid include generic levothyroxine tablets (multiple manufacturers) and, in some cases, Synthroid (brand levothyroxine tablet), subject to prior authorization requirements [7].

A prior authorization request for Tirosint on Montana Medicaid requires documentation of medical necessity, and the program has historically denied those requests on the basis that generic levothyroxine is therapeutically equivalent for the majority of hypothyroid patients. Patients with absorption disorders who fail tablet therapy face a difficult appeals process, and success rates are low without a specialist's written support letter.

Montana's Medicaid program is administered through the Montana Department of Public Health and Human Services (DPHHS) under a fee-for-service structure for most adult enrollees. The DPHHS Pharmacy Services division publishes the preferred drug list quarterly, and Tirosint has not appeared on the covered list in any recent quarter [7]. Patients who believe they have a medically compelling case should work with an endocrinologist to submit a formal exception request with TSH trend data, documentation of the absorption disorder (such as a positive urea breath test for H. pylori or confirmed autoimmune gastritis on biopsy), and a letter of medical necessity.

The Centers for Medicare and Medicaid Services has separately noted that Medicare Part D formularies vary by plan, and some Part D plans operating in Montana do include Tirosint on Tier 3 or Tier 4 with prior authorization [8]. Montana patients over 65 or on Medicare disability should check their specific plan's formulary at the plan's website or through the Medicare Plan Finder tool rather than assuming non-coverage.

Which Commercial Insurance Plans Cover Tirosint in Montana?

Coverage for Tirosint on commercial insurance in Montana depends entirely on the specific plan's formulary. No state mandate requires Montana commercial insurers to cover Tirosint over generic levothyroxine. Common patterns across major insurers operating in Montana include:

Blue Cross Blue Shield of Montana places Tirosint on a non-preferred brand tier (typically Tier 3 or Tier 4) with prior authorization required. Cost-sharing after PA approval ranges from roughly $50 to $120 per 30-day supply depending on deductible status [9].

PacificSource, which covers a significant portion of Montana individual and small-group market enrollees, similarly places Tirosint as non-preferred with prior authorization. PacificSource's formulary, updated annually, requires demonstration that the patient has tried and failed or has a contraindication to generic levothyroxine tablet therapy [9].

Cigna and Aetna plans available through Montana employers generally require PA for any brand levothyroxine product. Step therapy (requiring trial of generic tablet first) is standard. Patients who have already documented tablet failure before switching providers may have that history accepted as evidence to bypass the step therapy requirement, but the PA submission must include those records explicitly.

A 2022 analysis published in JAMA Internal Medicine found that branded thyroid hormone preparations face non-preferred formulary status in over 78% of commercial formularies nationally, reflecting payers' view that bioequivalence between generic levothyroxine and brand products is adequate for most patients [10]. Montana plans generally track this national pattern.

How Does the IBSA Savings Card Work in Montana?

IBSA, the manufacturer of Tirosint, offers a co-pay savings card program directly on the Tirosint website. Commercially insured patients who are not enrolled in a federal or state government health program (including Medicare, Medicaid, TRICARE, or VA) may qualify. The card reduces out-of-pocket cost to as low as $0 per month for eligible patients, subject to a monthly maximum savings cap and annual benefit limit set by IBSA [11].

To use the card in Montana, a patient presents it at any retail pharmacy that dispenses Tirosint at the time of pickup. The card is accepted at most major chain pharmacies (Walgreens, CVS, Walmart Pharmacy) and at independent pharmacies that participate in the IBSA program. Mail-order pharmacies may also accept it, though patients should confirm eligibility before filling.

The savings card does not work for Medicaid patients or Medicare beneficiaries. Federal anti-kickback regulations prohibit manufacturer savings cards from being applied to government-funded insurance plans. Montana patients on Medicaid who receive Tirosint through any workaround that allows the savings card to be applied may inadvertently create a billing compliance issue; this is a real risk that patients and prescribers should understand clearly.

IBSA also maintains a patient assistance program for uninsured or underinsured patients who meet income criteria, separate from the commercial savings card. Income thresholds and documentation requirements are listed on the IBSA website and are subject to annual revision [11].

Is Compounded Levothyroxine Legal in Montana, and Is It a Real Option?

Compounded levothyroxine gel capsules and liquid preparations are legal in Montana when prepared by a licensed 503A compounding pharmacy operating under Montana Board of Pharmacy oversight. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound medications for individual patients with a valid prescription [12].

Montana has not issued additional state-level restrictions on compounding levothyroxine beyond federal 503A requirements. A Montana-licensed prescriber can write a prescription for compounded levothyroxine gel capsules specifying a particular dose, base, and excipient profile, and a licensed 503A pharmacy within or outside Montana (shipping to Montana patients) can fill it lawfully.

The cost difference is substantial. Compounded levothyroxine gel capsules at licensed 503A pharmacies typically run $15 to $50 per month depending on dose and pharmacy, compared to $230 per month for branded Tirosint. For patients whose primary need is a dye-free or filler-free formulation rather than the specific IBSA product itself, a compounded gel capsule may achieve the same clinical goal at a fraction of the cost.

The American Thyroid Association has expressed caution about compounded thyroid preparations, noting that potency, stability, and sterility standards for compounded products are not subject to the same FDA manufacturing oversight as approved drug products [13]. A 2013 FDA report on compounding pharmacy quality found significant potency variability in samples of compounded thyroid hormone products, with some falling outside the 90 to 110 percent labeled potency range that FDA requires for approved levothyroxine products [14]. Patients and clinicians considering the compounded route should select a pharmacy with current USP 795 compliance documentation and request a certificate of analysis for the compounded product.

Absorption from a compounded gel capsule has not been studied in the same prospective trials as Tirosint. Vita et al. (2014) specifically studied an IBSA liquid levothyroxine product; extrapolating those absorption benefits directly to a compounded preparation is not scientifically supported without independent verification [1]. TSH monitoring at 6 to 8 weeks after switching to any compounded preparation is standard of care per the American Association of Clinical Endocrinology thyroid disease guidelines [15].

Can a Montana Patient Get Tirosint Through Telehealth?

Yes. Telehealth prescribing of Tirosint is legal in Montana. Montana allows prescribers licensed in Montana to conduct synchronous audio-video visits and issue valid prescriptions for non-controlled medications including levothyroxine products. The prescription can then be sent electronically to any Montana-licensed retail or compounding pharmacy [16].

The Montana Telehealth Alliance has documented that over 40% of Montana residents live in areas designated as Health Professional Shortage Areas, making telehealth a primary access route for endocrine care in much of the state [16]. A patient in, say, Havre or Sidney may have no endocrinologist within 100 miles but can access one via telehealth.

HealthRX operates in Montana and can prescribe Tirosint or a compounded levothyroxine gel capsule following a clinical intake, review of prior TSH records, and a synchronous video visit. The prescriber will confirm the clinical indication, check for drug interactions (particularly with calcium supplements, iron, and proton pump inhibitors given the absorption data above), and select the appropriate starting or continuation dose. Follow-up TSH is ordered at 6 to 8 weeks per standard protocol [15].

Prescribers writing levothyroxine via telehealth in Montana must be licensed in Montana or hold a valid Interstate Medical Licensure Compact (IMLC) license recognized by the Montana Board of Medical Examiners. Patients should verify their telehealth provider meets this requirement before scheduling.

TSH Monitoring: What to Expect After Starting Tirosint

Starting or switching to Tirosint requires the same TSH monitoring schedule as any levothyroxine formulation change. The American Thyroid Association recommends checking TSH 6 to 8 weeks after any dose or formulation change, given levothyroxine's long half-life of approximately 7 days and the corresponding 5 to 6 week period needed to reach steady state [13].

Patients switching from generic levothyroxine tablets to Tirosint at the same nominal dose should not assume TSH will remain stable. Vita et al. (2014) showed that absorption can improve by a clinically meaningful margin with the gel-cap or liquid form, meaning some patients will experience a reduction in TSH that falls below their target range, requiring a dose reduction [1]. A baseline TSH before the switch, then a repeat at 6 to 8 weeks, is the minimum monitoring standard.

Patients on thyroid cancer surveillance who use levothyroxine for TSH suppression face the same monitoring requirement, with a TSH goal below 0.1 mIU/L for high-risk patients per American Thyroid Association differentiated thyroid cancer guidelines [13]. Any formulation switch in that population should be treated as a pharmacokinetic variable that needs immediate re-verification.

Home thyroid testing kits cannot substitute for a laboratory TSH in this context. Commercial laboratory TSH assays certified under CLIA standards are required for clinical decision-making. HealthRX orders TSH through standard CLIA-certified national laboratory networks (Quest Diagnostics or LabCorp) with Montana draw sites available in most counties.

Drug Interactions That Affect Tirosint Specifically

The FDA-approved Tirosint labeling identifies several agents that reduce levothyroxine absorption even in the gel capsule formulation [3]. These include:

Calcium carbonate reduces levothyroxine absorption by up to 39% when taken simultaneously, per a study published in the New England Journal of Medicine (N=20) [17]. Patients should separate calcium from Tirosint by at least 4 hours.

Ferrous sulfate (iron) decreases absorption by a similar mechanism. A prospective study (N=14) published in the Annals of Internal Medicine showed a 37% reduction in levothyroxine bioavailability when iron was co-administered [18]. The same 4-hour separation rule applies.

Proton pump inhibitors reduce gastric acid production and may partially attenuate the absorption advantage of gel-cap levothyroxine over tablets, though the gel-cap form still shows superior absorption relative to tablets in low-acid environments per the Vita et al. data [1]. Patients on omeprazole, pantoprazole, or similar agents should inform their prescriber.

Cholestyramine and other bile acid sequestrants can reduce levothyroxine absorption by over 90% when taken together [3]. These should be separated by at least 4 to 6 hours from any levothyroxine formulation.

Cost Comparison: Your Four Options as a Montana Patient

| Option | Estimated Monthly Cost | Requires PA | Medicaid Eligible | |---|---|---|---| | Generic levothyroxine tablet (GoodRx) | $4 to $15 | No | Yes | | Tirosint (IBSA savings card, commercially insured) | $0 to $35 | Often yes | No | | Tirosint (cash pay, no discount) | ~$230 | No | No | | Compounded levothyroxine gel cap (503A pharmacy) | $15 to $50 | No | No (cash pay) |

Generic levothyroxine tablets remain the first-line option for most patients and the only option that Montana Medicaid covers reliably [7]. Tirosint through the IBSA savings card is the most cost-effective route for commercially insured Montana patients who meet the absorption-disorder criteria and can get PA approved. The compounded gel capsule is the most accessible low-cost alternative for uninsured patients who need a filler-free formulation but should be paired with close TSH monitoring given the lack of FDA manufacturing oversight [14].